The Medios Individualized Cytostatic Preparations - Behind the tailored cancer therapies for German pharmacies

By Daniel Foster, ad hoc news Software & Services Desk. Reviewed July 02, 2026, 8:51 AM ET. Details in the imprint.

Medios Individualized Cytostatic Preparations sit behind a glass barrier, with clear bags and syringes marked with a single patient’s name and dose. A pharmacy technician in full protective gear checks each label under bright white light before the chemotherapy mix leaves the cleanroom.

What these preparations deliver

Medios, a German specialty pharma provider focused on individualized medicine, offers cytostatic preparations as a service to partner pharmacies, mainly for cancer patients across Germany. Each preparation is compounded specifically for one prescription and one person, using cytostatics such as paclitaxel or platinum-based agents.

According to Medios CEO Matthias Gärtner, the company’s network of certified compounding pharmacies prepares these oncology therapies under strict GMP-like standards to support safer cancer care and reduce workload for hospital and retail pharmacies. The service is not a shelf product but an individualized, just-in-time mix delivered on the day of treatment.

How the service works in practice

On Medios’ German-language service pages, the company describes individualized cytostatic preparations as part of its "Therapy-related individualized medicine" offering, where pharmacies send orders electronically and receive finished sterile oncology preparations back, ready for administration. The compounding center adjusts dosage to body surface area, renal function, and the specific regimen prescribed by the oncologist.

In a typical workflow, a hospital pharmacy connects to Medios through a contractual cooperation: once the oncologist signs off a protocol, the prescription data are routed to the Medios compounding site, where staff calculate exact doses, prepare the infusions in laminar airflow hoods, and apply clear documentation for each step, including batch numbers and expiry.

Quality control and safety focus

Unlike conventional finished-dose oncology drugs shipped directly by manufacturers, Medios’ individualized cytostatic preparations are partly based on bulk medications that are then reconstituted and dosed for one patient by compounding staff, a process that requires rigorous aseptic technique. The company highlights multi-level quality assurance, with in-process checks, plausibility controls, and documentation designed to reduce medication errors.

German regulators set a high bar for sterile compounding, and Medios reports that its sites operate under the relevant pharmacy regulations and use cleanrooms with defined air quality classes. Temperature and humidity are monitored, and cytostatics handling includes protective measures for workers, such as closed transfer systems and personal protective equipment to limit exposure.

Why US investors should care

Medios primarily serves the German market, so US patients will not encounter these individualized cytostatic preparations at their local oncology centers. However, the business model parallels US sterile compounding services that prepare chemotherapy infusions for hospital systems, a known niche in healthcare services.

For US-based investors looking at European healthcare names, Medios’ emphasis on individualized oncology and rare disease therapies positions it in a specialized corner of the pharma services market, where revenues are linked to treatment volumes and pharmacy partnerships rather than direct consumer sales. Shares of Medios (Xetra: M8S) provide exposure to this compounding-driven model without a US listing.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.